BioMarin Pharmaceutical Inc. Files 8-K Report

TL;DR

BioMarin filed an 8-K on 12/19/25, reporting a material definitive agreement and financial updates.

AI Summary

On December 19, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and included a Regulation FD Disclosure. It also provided financial statements and exhibits.

Why It Matters

This 8-K filing signals significant corporate events or agreements for BioMarin Pharmaceutical Inc., which could impact its business operations and financial standing.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report detailing corporate events and agreements, not indicating immediate financial distress or significant new risks.

Key Players & Entities

• BioMarin Pharmaceutical Inc. (company) — Registrant
• December 19, 2025 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 B — ich registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market I
• $0.01 — share of Amicus common stock, par value $0.01 per share (the " Shares "), issued and
• $14.50 — and converted into the right to receive $14.50 per Share in cash, without interest the
• $175,000,000 — ed to pay BioMarin a termination fee of $175,000,000. Such circumstances include where the M
• $3.65 billion — principal amount of up to approximately $3.65 billion in the form of a 364-day senior secured

Filing Documents

• d49247d8k.htm (8-K) — 55KB
• d49247dex21.htm (EX-2.1) — 584KB
• d49247dex991.htm (EX-99.1) — 47KB
• g49247dsp1.jpg (GRAPHIC) — 7KB
• g49247dsp1a.jpg (GRAPHIC) — 7KB
• 0001193125-25-325856.txt ( ) — 989KB
• bmrn-20251219.xsd (EX-101.SCH) — 3KB
• bmrn-20251219_lab.xml (EX-101.LAB) — 17KB
• bmrn-20251219_pre.xml (EX-101.PRE) — 11KB
• d49247d8k_htm.xml (XML) — 3KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 2.1* Agreement and Plan of Merger, dated as of December 19, 2025, by and among Amicus Therapeutics, Inc., BioMarin Pharmaceutical Inc., and Lynx Merger Sub 1, Inc. 99.1 Joint Press Release issued by BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. on December 19, 2025 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. * Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. BioMarin agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon request; provided, however, that BioMarin may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule so furnished.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements about, among other things, the proposed acquisition of Amicus by BioMarin and the business prospects of Amicus and BioMarin, including, without limitation, statements about: the anticipated occurrence, manner and timing of the closing of the proposed acquisition and the availability of financing, including the proposed non-convertible debt financing; the prospective benefits of the proposed acquisition, including expectations that it will accelerate BioMarin's revenue growth and strengthen its financial outlook immediately upon close, increase BioMarin's long-term CAGR through 2030 and beyond, strengthen and diversify BioMarin's commercial portfolio and be a strong strategic fit for BioMarin by expanding BioMarin's rare disease product portfolio, create substantial shareholder value by being accretive to Non-GAAP Diluted EPS in the first 12 months after close and substantially accretive beginning in 2027; BioMarin's commitment to deleveraging and the expectation that BioMarin will reach gross leverage <2.5x within two years after close; expectations regarding Amicus' products, Galafold and Pombiliti + Opfolda, including ability to expand access to patients in new markets across BioMarin's global footprint; expectations regarding Amicus' product candidate, DMX-200, and its ongoing development, including the potential for DMX-200 to be the first-in-class investigational small molecule for the treatment of focal segmental glomerulosclerosis (FSGS); expectations regarding the settlement of the patent litigation relating to Galafold, including expectations that U.S. exclusivity for Galafold will be through January 2037; BioMarin's capital allocation strategy to leverage its financial strength to diversify its pipeline and add innovative new therapies for patients; the potential impact of the acquisition on BioMarin's financial results and financial guidance; BioMarin's plans

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BioMarin Pharmaceutical Inc., a Delaware corporation Date: December 19, 2025 By: /s/ G. Eric Davis G. Eric Davis Executive Vice President, Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR